Key facts
- This page summarizes Michael Terrence Gibbs's Form 4 filing for T2 Biosystems, Inc. (TTOO).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 02 Jan 2025, 18:20.
Michael Terrence Gibbs - 04 Nov 2024 Form 4 Insider Report for T2 Biosystems, Inc. (TTOO)
- Reporting relationship
- General Counsel
- Issuer ticker
- TTOO
- Reported as of
- 04 Nov 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Jan 2025, 18:20:19 UTC
- Prior SEC filing
- 27 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ John Sprague, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Michael Terrence Gibbs filed Form 4 for T2 Biosystems, Inc. (TTOO) on 02 Jan 2025.
Change
- Previous filing in this sequence was filed on 27 Feb 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TTOO
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +190,000
- Change %
- Price
- $0.000000
- Shares after
- 190,000
- Date
- 04 Nov 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 190,000
- Exercise price
- Footnotes
- F1, F2
TTOO
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +190,000
- Change %
- Price
- $0.000000
- Shares after
- 190,000
- Date
- 04 Nov 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 190,000
- Exercise price
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
Footnote F2
On November 4, 2024, the reporting person was granted 190,000 RSU's that vest in one installment on May 4, 2025. This grant was contingent on stockholder approval of the amendment and restatement of Issuer's 2014 Incentive Award Plan. The Issuer's stockholders approved the amendment and restatement of the plan on December 30, 2024.
Footnote F3
On November 4, 2024, the reporting person was granted 190,000 RSU's that vest in three equal annual installments beginning on November 4, 2025. This grant was contingent on stockholder approval of the amendment and restatement of Issuer's 2014 Incentive Award Plan. The Issuer's stockholders approved the amendment and restatement of the plan on December 30, 2024.